News Story: Full Text
Sponsored By
Medicenna Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.


Posted on: 11/22/2006

J Neurooncol. 2006 Oct 4; [Epub ahead of print] Related Articles, Links

 
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.

Chamberlain MC, Chalmers L.

Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Avenue, Tampa, FL, 33612-0804, USA, ChambeMC@moffitt.usf.edu.

There is no standard of care for elderly patients (age >/= 70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4-14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.

PMID: 17019532 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites